Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jan 3;17(1):e255011.
doi: 10.1136/bcr-2023-255011.

Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis

Stephanie Ong  1 , Joseph Kibbler  2   3 , Gemma Maxwell  1 , John Steer  3
Affiliations
Case Reports

Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis

Stephanie Ong et al. BMJ Case Rep. .

Abstract

Fingolimod is a sphingosine-1-phosphate receptor modulator approved as a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (MS). A woman in her 30s was treated with fingolimod for relapsing-remitting MS. After 7 years of treatment, she presented with non-productive cough, night sweats, breathlessness and unintentional weight loss. She had a negative interferon-gamma release assay (IGRA). A high-resolution CT thorax showed innumerable miliary opacities in both lungs. Bronchoalveolar lavage was positive for Mycobacterium tuberculosis complex PCR. An MRI head showed multiple small punctate contrast-enhancing lesions most typical for tuberculomas. We describe the first reported case of disseminated tuberculosis (TB) associated with fingolimod treatment. Patients who are receiving DMT must be closely observed for the development of opportunistic infections, and IGRA results should be interpreted with caution. Screening for latent TB prior to commencing fingolimod should be considered on an individual basis. The management of TB in MS patients on DMT requires an interdisciplinary approach.

Keywords: Infectious diseases; Multiple sclerosis; Neurology; TB and other respiratory infections.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

  • Histoplasmosis in a fingolimod-treated patient: case report and scoping review.
    Oliveira VF, Silva GDD, Silva LT, Gonçalves VL, Rivas PE, Marques AC, Taborda M, Magri ASGK, Apóstolos-Pereira SL, Callegaro D, Magri MMC. Oliveira VF, et al. Rev Inst Med Trop Sao Paulo. 2024 Jul 8;66:e39. doi: 10.1590/S1678-9946202466039. eCollection 2024. Rev Inst Med Trop Sao Paulo. 2024. PMID: 39052026 Free PMC article.

References

    1. Zhao Z, Ma C-L, Gu Z-C, et al. . Incidence and risk of infection associated with Fingolimod in patients with multiple sclerosis: A systematic review and meta-analysis of 8,448 patients from 12 randomized controlled trials. Front Immunol 2021;12:611711. 10.3389/fimmu.2021.611711 - DOI - PMC - PubMed
    1. Köseoğlu M, Gözübatık Çelik RG, Kürtüncü M. A case report with tuberculous meningitis during Fingolimod treatment. Mult Scler Relat Disord 2020;46:102450. 10.1016/j.msard.2020.102450 - DOI - PubMed
    1. Calabresi PA, Radue E-W, Goodin D, et al. . Safety and efficacy of Fingolimod in patients with relapsing remitting multiple sclerosis (FREEDOMS) a double blind randomised placebo controlled phase 3 trial. The Lancet Neurology 2014;13:545–56. 10.1016/S1474-4422(14)70049-3 - DOI - PubMed
    1. Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018;5. 10.1093/ofid/ofy174 - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellent . Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. (NICE technology appraisal guidance Ta254. 2012. Available: https://www.nice.org.uk/guidance/ta254 [Accessed 16 Jan 2023].

Publication types

LinkOut - more resources